Surge in Carbon Credit Platforms Signals Shift Toward Profitable Climate Action
The global Carbon Credit Trading Platform Market, valued at USD 146.2 million in 2024, is projected to surge to USD 724.0 million by 2035, growing at a robust CAGR of 17.6%. This growth is driven by increasing global focus on emissions reduction, rising corporate sustainability efforts, and a widespread shift toward achieving net-zero emissions targets.
In a comprehensive analysis led by Shweta R., Business Development Specialist at Prophecy Market Insights, the evolving landscape of carbon trading platforms is explored in depth, highlighting market dynamics, opportunities, and competitive strategies.
Carbon credit trading platforms enable organizations to offset their greenhouse gas emissions by purchasing carbon credits tied to verified environmental projects. These platforms are gaining momentum as governments implement stricter climate regulations and businesses prioritize environmental accountability. The market is segmented by type (voluntary and regulated markets), system type (cap-and-trade, baseline-and-credit), end-use industries (industrial, utilities, energy, petrochemical, aviation, and others), and by region.
Several key factors are accelerating market growth:
1. Government and Intergovernmental Policies: Programs like the EU Emissions Trading System (EU ETS) and California's Cap-and-Trade initiative are compelling businesses to participate in carbon trading, expanding platform adoption.
2. Corporate Net-Zero Commitments: A growing number of multinational companies are setting voluntary net-zero goals, fueling demand for high-quality carbon credits and reliable platforms for tracking and compliance.
Despite its potential, the market faces several challenges:
· Lack of Standardization: Inconsistencies in carbon credit quality, verification methods, and pricing across markets create uncertainty.
· Limited Awareness: Especially in developing regions, understanding of carbon trading remains low, and supporting infrastructure is still emerging.
· Growth in Emerging Economies: Asia-Pacific and Latin America are seeing increased government support for carbon pricing. As policy frameworks and infrastructure develop, these regions will become key growth areas.
· Decentralized Markets: Blockchain-based platforms are lowering entry barriers and improving transparency, creating opportunities for small-scale traders and new market entrants.
The market includes a diverse mix of global exchanges, environmental consultancies, and tech-driven startups. Leading players include:
· Nasdaq, Inc.
· CME Group Inc.
· ACX (AirCarbon Exchange)
· XPANSIV
· ClimeCo LLC
· VERRA
· South Pole
· Rubicon Carbon Services
· European Energy Exchange AG
· Carbonplace
· ClimateTrade
· SCB Group
· Cloverly
· Envex
· ecoact
These companies are leveraging technologies such as AI for credit assessment, blockchain for traceability, and digital platforms to streamline trading processes.
· North America leads the market, driven by strong regulatory support, corporate leadership in sustainability, and advanced digital infrastructure.
· Europe is a close second, supported by comprehensive climate policies and the longstanding EU ETS framework.
· Asia-Pacific is the fastest-growing region, propelled by industrial expansion and evolving environmental regulations in countries like China, India, and Japan.
· Latin America and MEA are emerging markets, gaining traction with increased interest in climate finance and international carbon offset projects.
To maximize growth potential, stakeholders should:
· Invest in platform transparency through blockchain and third-party verification.
· Engage with regulators to support consistent standards.
· Promote education and awareness in underserved markets.
As global efforts to combat climate change intensify, carbon credit trading platforms will become essential tools in achieving sustainability goals. With rapid digital transformation and regulatory alignment underway, this sector presents a high-growth opportunity for innovators, investors, and policymakers alike.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss. In five years, the stock has soared by close to 480%, which would have turned a $20,000 investment into approximately $116,000. The GLP-1 market is still in its early growth stages, and there's plenty of room for more companies to make names for themselves. While Eli Lilly is a safe bet to invest in right now, if you want a position in stocks that may have considerably more upside in the GLP-1 market, there are two names you should take a closer look at today: Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT). The big excitement surrounding Viking is it has a GLP-1 treatment that could be a viable option for weight loss. VK2735 isn't an approved treatment yet, but it has been showing encouraging results in early-stage trials. In data released last year, a phase 2 trial showed that the drug was able to help patients lose up to 14.7% of their body weight after 13 weeks, without signs of any plateau, suggesting further weight loss could be possible. Phase 3 trials are set to begin this year. Meanwhile, Viking is also working on an oral version of the treatment, which is currently in phase 2 trials. The phase 1 data from that looked solid, with trial participants losing up to 8.2% of their body weight after 28 days. The risk with Viking is that it isn't generating revenue today, and it doesn't have any approved products. It has incurred a net loss totaling $128 million over the trailing 12 months, and there's a real possibility that those losses could deepen as it spends more on clinical trials. If VK2735 isn't successful and doesn't obtain approval from regulators, the stock could nosedive, which is the biggest concern for investors. Investors have largely looked past Viking this year, as the healthcare stock is down 35% (as of June 13), pulling its market cap down to less than $3 billion. However, if there's encouraging clinical data to come out in the future, that could trigger a rally in Viking's stock. This is a company that has a lot of upside, and if you're OK with taking on some risk, this may be a good stock to invest in a modest amount of money into. Altimmune is similar to Viking, but it's much smaller in market capitalization, worth less than $600 million. It hasn't been as popular of an option for investors, but it's an investment that may have even greater upside, given its more modest valuation. It also has a promising GLP-1 product that investors are bullish on: pemvidutide. In a phase 2 trial, participants lost an average of 15.6% of their body weight after a period of 48 weeks on the highest dosage (2.4 mg). The company doesn't have an oral version in development, but it is also testing pemvidutide as a treatment for other conditions, including metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol liver disease. Altimmune generates limited revenue (primarily coming from grants and contracts), and until and unless it obtains approval for pemvidutide, that's likely to stay this way. Over the past four quarters, its losses have totaled $90 million, and it has burned through more than $80 million just from its day-to-day operating activities. With around $150 million in cash and short-term investments, it's adequately funded, but there is high likelihood of share offerings being necessary in the future, and dilution is a real concern for investors. If pemvidutide becomes a success, Altimmune could easily double or triple in value and potentially be an acquisition target for a larger healthcare company seeking opportunities in GLP-1. There's risk with Altimmune, but there could also be tremendous upside. If you can stomach the uncertainty, you may want to consider taking a chance on the stock. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 34 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on June 16, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock option awards have an exercise price of $51.87 per share, the closing price of PTC's common stock on June 16, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. ABOUT PTC THERAPEUTICS, is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit and follow on Facebook, X, and LinkedIn. For more information please contact: Investors:Ellen Cavaleri+1 (615) 618-8228ecavaleri@ Media:Jeanine Clemente+1 (908) 912-9406jclemente@ View original content to download multimedia: SOURCE PTC Therapeutics, Inc. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
3 Stocks Under $10 with Open Questions
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn't mean they're bargains though, and we urge investors to be careful as many have risky business models. The bad behavior exhibited by lower-quality companies in this space can spook even the most seasoned professionals, which is why we started StockStory - to separate the good from the bad. Keeping that in mind, here are three stocks under $10 to avoid and some other investments you should consider instead. Share Price: $7.16 With courses ranging from investing to cooking to computer programming, Udemy (NASDAQ:UDMY) is an online learning platform that connects learners with expert instructors who specialize in a wide range of topics. Why Are We Wary of UDMY? Customer spending has dipped by 1.6% on average as it focused on growing its buyers Sales are projected to remain flat over the next 12 months as demand decelerates from its three-year trend High marketing expenses suggest it needs to spend heavily on new customer acquisition to sustain momentum Udemy's stock price of $7.16 implies a valuation ratio of 11.1x forward EV/EBITDA. Dive into our free research report to see why there are better opportunities than UDMY. Share Price: $0.74 Founded by two brothers, Purple (NASDAQ:PRPL) creates sleep and home comfort products such as mattresses, pillows, and bedding accessories. Why Should You Dump PRPL? Sales tumbled by 6.3% annually over the last two years, showing consumer trends are working against its favor Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Purple is trading at $0.74 per share, or 24.6x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why PRPL doesn't pass our bar. Share Price: $1.33 Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Why Should You Sell PACB? Sales trends were unexciting over the last two years as its 6.6% annual growth was below the typical healthcare company Free cash flow margin dropped by 29.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up Short cash runway increases the probability of a capital raise that dilutes existing shareholders At $1.33 per share, PacBio trades at 2.4x forward price-to-sales. To fully understand why you should be careful with PACB, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
